Tuberculosis Vaccine Market – Global Trends, 2026


Posted June 14, 2018 by Rupesh_D

Tuberculosis Vaccine Market report categorizes the global market by type of vaccine (Viral Vector Vaccine, Recombinant Protein Vaccine, Recombinant BCG Vaccine, Attenuated Vaccine, and Others) and by geography

 
Tuberculosis (TB) is a highly contagious disease caused by the bacterium known as Mycobacterium tuberculosis and is mostly spread through person to person contact. It causes multisystem infection and eventually might lead to death of the infected person. Two types of TB that are commonly observed include latent TB in which the infected person do not show symptoms and active TB in which the infected person shows clinical symptoms of TB. Clinical symptoms and signs of TB include fever, night sweats, cough, weight loss, hemoptysis (coughing up blood-stained sputum), fatigue, chest pain, and shortness of breath. Depending upon the symptoms, TB may be classified as pulmonary TB, subcutaneous TB or military TB.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1602

Depending on the resistance it shows, TB may be multidrug resistant TB or extended drug resistant TB. Diagnosis of tuberculosis can be carried out using skin test, polymerase chain reaction test or interferon-gamma release assays. Initial treatment regime for active TB includes drugs such as ethambutol, pyrazinamide, isoniazid, and rifampicin. Although currently no TB vaccine is approved commercially, children are vaccinated with BCG vaccine as a part of precautionary measure. However, BCG vaccine has limited utility and variable efficacy in both adults and children. Many TB vaccines are under the stage of clinical development, which are expected to reach the market in the near future.

Tuberculosis account for the highest amount of death caused due to infectious disease across the globe. According to the World Health Organization (WHO) factsheet 2018 on TB, 10.4 million people fell ill with TB in 2016 and 1.7 million people with TB died in the same year. More than 95% of TB deaths occur in low- and middle-income economies. Deaths caused due to TB also includes death of 0.4 million people infected with HIV. Such high number of patients across the world confirms the enormity of disease and urgent requirements for vaccines worldwide. Therefore, the launch of tuberculosis vaccine would gain significant revenue and in turn, would propel the market growth.

Click To Continue Reading on Tuberculosis Vaccine Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Visit our news Website: https://www.coherenttimes.org/
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Mr. Shah
Phone 2067016702
Business Address 1001 4th Ave, #3200
Country United States
Categories Medical , Research
Tags tuberculosis vaccine market , tuberculosis vaccine market insights
Last Updated June 14, 2018